[go: up one dir, main page]

HUP0202152A2 - Tricyclyc farnesyl protein transferase inhibitors - Google Patents

Tricyclyc farnesyl protein transferase inhibitors

Info

Publication number
HUP0202152A2
HUP0202152A2 HU0202152A HUP0202152A HUP0202152A2 HU P0202152 A2 HUP0202152 A2 HU P0202152A2 HU 0202152 A HU0202152 A HU 0202152A HU P0202152 A HUP0202152 A HU P0202152A HU P0202152 A2 HUP0202152 A2 HU P0202152A2
Authority
HU
Hungary
Prior art keywords
tricyclyc
protein transferase
transferase inhibitors
farnesyl protein
farnesyl
Prior art date
Application number
HU0202152A
Other languages
English (en)
Hungarian (hu)
Inventor
Adriano Afonso
Cynthia J Aki
Carmen Alvarez
Jianping Chao
Alan B Cooper
Jagdish A Desai
Ronald J Doll
Johan A Ferreira
Viyyoor M Girijavallabhan
Timothy J Guzi
Joseph M Kelly
Tarik Lalwani
Alan K Mallams
Dinanath F Rane
Arthur G Taveras
James J S Wang
Jay Weinstein
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HUP0202152A2 publication Critical patent/HUP0202152A2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electroluminescent Light Sources (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0202152A 1998-12-18 1999-12-16 Tricyclyc farnesyl protein transferase inhibitors HUP0202152A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21639898A 1998-12-18 1998-12-18

Publications (1)

Publication Number Publication Date
HUP0202152A2 true HUP0202152A2 (en) 2002-10-28

Family

ID=22806914

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202152A HUP0202152A2 (en) 1998-12-18 1999-12-16 Tricyclyc farnesyl protein transferase inhibitors

Country Status (20)

Country Link
EP (1) EP1140902A1 (pt)
JP (1) JP2002533336A (pt)
KR (1) KR20010081116A (pt)
CN (1) CN1326850C (pt)
AR (1) AR021718A1 (pt)
AU (1) AU776558B2 (pt)
BR (1) BR9916314A (pt)
CA (1) CA2354779A1 (pt)
CO (1) CO5160350A1 (pt)
CZ (1) CZ20011950A3 (pt)
HU (1) HUP0202152A2 (pt)
IL (1) IL143408A0 (pt)
NO (1) NO20012961L (pt)
NZ (1) NZ511878A (pt)
PE (1) PE20001342A1 (pt)
PL (1) PL348293A1 (pt)
SK (1) SK7592001A3 (pt)
TR (1) TR200101755T2 (pt)
WO (1) WO2000037459A1 (pt)
ZA (1) ZA200104233B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021718A1 (es) 1998-12-18 2002-07-31 Schering Corp Inhibidores de transferasa de proteina farnesilo.
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
US6645966B2 (en) 2001-01-22 2003-11-11 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
WO2002080895A2 (en) * 2001-04-06 2002-10-17 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
MX2007007074A (es) 2004-12-13 2007-09-04 Schering Corp Inhibidores novedosos de proteina transferasa de farnesilo y su uso para tratar cancer.
CA2591123A1 (en) 2004-12-14 2006-06-22 Schering Corporation Farnesyl protein transferase inhibitors and methods for treating proliferative diseases
CA2637572A1 (en) * 2006-01-19 2007-07-26 Schering Corporation Piperazine derivatives as farnesyl protein transferase inhibitors
CN106103424A (zh) * 2014-03-19 2016-11-09 维亚梅特制药公司 2‑(2,4‑二氟苯基)‑1,1‑二氟‑1‑(5‑经取代的吡啶‑2‑基)‑3‑(1h‑四唑‑1‑基)丙烷‑2‑醇和其制备方法
EP3119756B9 (en) 2014-03-19 2021-08-25 Dow AgroSciences LLC 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US5712280A (en) * 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5801175A (en) * 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
PE92098A1 (es) * 1996-07-31 1998-12-31 Schering Corp N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo
CN1266433A (zh) * 1997-06-17 2000-09-13 先灵公司 用于抑制法呢基蛋白转移酶的苯并吡啶并环庚烷化合物
AR021718A1 (es) 1998-12-18 2002-07-31 Schering Corp Inhibidores de transferasa de proteina farnesilo.

Also Published As

Publication number Publication date
WO2000037459A1 (en) 2000-06-29
NZ511878A (en) 2003-10-31
KR20010081116A (ko) 2001-08-27
AR021718A1 (es) 2002-07-31
CO5160350A1 (es) 2002-05-30
NO20012961L (no) 2001-08-16
SK7592001A3 (en) 2002-03-05
TR200101755T2 (tr) 2001-09-21
BR9916314A (pt) 2001-10-02
PL348293A1 (en) 2002-05-20
EP1140902A1 (en) 2001-10-10
ZA200104233B (en) 2002-08-22
IL143408A0 (en) 2002-04-21
AU776558B2 (en) 2004-09-16
CN1334811A (zh) 2002-02-06
PE20001342A1 (es) 2000-12-09
CA2354779A1 (en) 2000-06-29
NO20012961D0 (no) 2001-06-15
JP2002533336A (ja) 2002-10-08
CZ20011950A3 (cs) 2001-12-12
AU2030700A (en) 2000-07-12
CN1326850C (zh) 2007-07-18

Similar Documents

Publication Publication Date Title
IL143409A0 (en) Farnesyl protein transferase inhibitors
ZA985778B (en) Inhibitors of farnesyl protein transferase.
PL330120A1 (en) Farnesilic protein transferase inhibitors
IL124197A (en) Inhibitors of farnesyl protein transferase
EP0918771A4 (en) THIADIOXOBENZODIAZEPINES FOR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS
HK1034450A1 (en) Farnesyl protein transferase inhibitors for treating arthropathies
EP1027042A4 (en) FARNESYL PROTEIN TRANSFERASE INHIBITORS
AU4020897A (en) 3-mercaptopyrrolidines as farnesyl protein transferase inhibitors
HUP0202152A2 (en) Tricyclyc farnesyl protein transferase inhibitors
AU2435199A (en) Farnesyl transferase inhibitors
PL355887A1 (en) Farnesyl transferase inhibitors
IL130453A0 (en) Farnesyl transferase inhibitors
AU3514302A (en) 0ovel farnesyl protein transferase inhibitors
IL141626A0 (en) Farnesyl transferase inhibitors
HUP9903221A3 (en) Inhibitors of protein farnesyl transferase
IL155594A0 (en) Farnesyl transferase inhibitors
ZA971254B (en) Farnesyl transferase inhibitors
SI0948483T1 (en) Farnesyl transferase inhibitors
IL149870A0 (en) Inhibitors of farnesyl protein transferase
ZA971621B (en) Inhibitors of farnesyl protein transferase

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees